BeStock  
Stocks › Biotechnology › MLTX

MoonLake Immunotherapeutics MLTX

US equityMarket cap rank #3205Biotechnology
$11.07 +$0.04 (+0.36%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $11.07 0.00%
Open$10.79
Prev close$11.03
Day range$10.73 – $11.31
Volume1.72M
Market cap$942.13M
P/E (TTM)–
Dividend yield–

MLTX Stock News

Headlines matching MoonLake Immunotherapeutics or the MLTX ticker, most recent first.

  • H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $50 PositiveMarket news · 13 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $34Market news · 11 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45Market news · 20 Jul 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)TipRanks · 9 Jun 2026 · Direct mention
  • Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30Market news · 9 Jun 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)TipRanks · 8 Jun 2026 · Direct mention
  • A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $70Market news · 23 Jun 2026 · Direct mention
  • A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $45Market news · 12 May 2026 · Direct mention
  • A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $70Market news · 11 May 2026 · Direct mention
  • BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30Market news · 8 Apr 2026 · Direct mention
  • H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40Market news · 15 Apr 2026 · Direct mention
  • Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25Market news · 14 Apr 2026 · Direct mention
  • Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)TipRanks · 31 Mar 2026 · Direct mention
  • Wolfe Research Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 PositiveMarket news · 23 Mar 2026 · Direct mention
  • Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Maintains Target Price $6Market news · 20 Mar 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on MLTX.

Sign in to join the discussion.

Scroll to Top